JP2019510737A - 高親和性ＩｇＥ受容体アルファ鎖（ＦｃｅＲＩａ） - Google Patents

高親和性ＩｇＥ受容体アルファ鎖（ＦｃｅＲＩａ） Download PDF

Info

Publication number
JP2019510737A
JP2019510737A JP2018536507A JP2018536507A JP2019510737A JP 2019510737 A JP2019510737 A JP 2019510737A JP 2018536507 A JP2018536507 A JP 2018536507A JP 2018536507 A JP2018536507 A JP 2018536507A JP 2019510737 A JP2019510737 A JP 2019510737A
Authority
JP
Japan
Prior art keywords
fceria
ige
apheresis
lysine
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018536507A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019510737A5 (cg-RX-API-DMAC10.html
Inventor
オスカー・スムルツカ
マルヴァ・モスタゲーア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affiris AG
Original Assignee
Affiris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris AG filed Critical Affiris AG
Publication of JP2019510737A publication Critical patent/JP2019510737A/ja
Publication of JP2019510737A5 publication Critical patent/JP2019510737A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3496—Plasmapheresis; Leucopheresis; Lymphopheresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2018536507A 2016-01-13 2017-01-13 高親和性ＩｇＥ受容体アルファ鎖（ＦｃｅＲＩａ） Withdrawn JP2019510737A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16020009.3 2016-01-13
EP16020009.3A EP3192806A1 (en) 2016-01-13 2016-01-13 Alpha chain of the high-affinity ige receptor (fceria)
PCT/EP2017/050646 WO2017121842A1 (en) 2016-01-13 2017-01-13 Alpha chain of the high-affinity ige receptor (fceria)

Publications (2)

Publication Number Publication Date
JP2019510737A true JP2019510737A (ja) 2019-04-18
JP2019510737A5 JP2019510737A5 (cg-RX-API-DMAC10.html) 2020-02-06

Family

ID=55357837

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018536507A Withdrawn JP2019510737A (ja) 2016-01-13 2017-01-13 高親和性ＩｇＥ受容体アルファ鎖（ＦｃｅＲＩａ）

Country Status (8)

Country Link
US (1) US20190127438A1 (cg-RX-API-DMAC10.html)
EP (2) EP3192806A1 (cg-RX-API-DMAC10.html)
JP (1) JP2019510737A (cg-RX-API-DMAC10.html)
CN (1) CN108473551A (cg-RX-API-DMAC10.html)
AU (1) AU2017207854A1 (cg-RX-API-DMAC10.html)
CA (1) CA3010982A1 (cg-RX-API-DMAC10.html)
RU (1) RU2018129024A (cg-RX-API-DMAC10.html)
WO (1) WO2017121842A1 (cg-RX-API-DMAC10.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022539684A (ja) * 2019-07-08 2022-09-13 ジーアイ イノベーション， インコーポレイテッド 高シアル酸含量を有し、ＩｇＥ Ｆｃ受容体のアルファサブユニットの細胞外ドメインを含むポリペプチド二量体及び同ポリペプチド二量体を含む医薬組成物
JP2023522574A (ja) * 2020-03-26 2023-05-31 ウニヴェルシテ トゥールーズ トロワジェーム－ポール サバティエ リウマチ性関節炎治療用アフェレシスカラム
JP2023534024A (ja) * 2020-07-17 2023-08-07 ジーアイ イノベーション， インコーポレイテッド Ｉｇｅ ｆｃ受容体アルファサブユニット細胞外ドメイン及び抗ｉｌ－４抗体を含む融合タンパク質並びにその融合タンパク質の使用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7780186B2 (ja) 2018-10-29 2025-12-04 コデクシス， インコーポレイテッド 操作されたｄｎａポリメラーゼバリアント
CN111100210B (zh) * 2019-01-30 2022-04-19 武汉九州钰民医药科技有限公司 一种Fc融合蛋白及其应用
EP3711772A1 (en) 2019-03-20 2020-09-23 Oslo Universitetssykehus HF Recombinant proteins and fusion proteins
CN110716054A (zh) * 2019-09-11 2020-01-21 天津医科大学 一种血清亲细胞性免疫球蛋白e的定量检测试剂盒
JP2026511640A (ja) * 2023-03-29 2026-04-14 グリフォルス・ワールドワイド・オペレーションズ・リミテッド ＦｃεＲＩβ自己抗体のレベルが低減された血漿製剤の組成物および調製方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4770774A (en) 1985-09-19 1988-09-13 Toray Industries, Inc. Column for removing β2 -microglobulin
US5985599A (en) 1986-05-29 1999-11-16 The Austin Research Institute FC receptor for immunoglobulin
US4962035A (en) 1987-12-01 1990-10-09 President And Fellows Of Harvard College DNA encoding IgE receptor alpha-subunit or fragment thereof
AU691297B2 (en) 1994-05-13 1998-05-14 Miltenyi Biotec Gmbh Sterile and pyrogen-free columns coupled to protein for binding and removal of substances from blood
IL116436A (en) * 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND
AR008077A1 (es) 1996-07-26 1999-12-09 Talarico Salinas Laura Beatriz Un polipeptido de fusion o una sal del mismo, su uso, un proceso para prepararlos, una composicion farmaceutica que los comprende, y un vector.
GB9715387D0 (en) 1997-07-23 1997-09-24 Gould Hannah J Immunoglobulin-binding polypeptides and their use
US6057127A (en) * 1998-01-29 2000-05-02 Heska Corporation Equine Fc epsilon receptor alpha chain nucleic acid molecules and uses thereof
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
CA2385778A1 (en) * 1999-09-21 2001-03-29 Isis Innovation Limited Modulation of ige receptor cell surface expression
AU2001273456A1 (en) * 2000-07-13 2002-01-30 Hyseq, Inc. Soluble immunoglobulin e receptor alpha like molecules
US8354109B2 (en) 2005-12-13 2013-01-15 Suppremol Gmbh Multimeric Fc receptor polypeptides
WO2012140214A1 (en) 2011-04-13 2012-10-18 Biomay Ag IMMUNOAFFINITY SEPARATION MATERIALS COMPRISING ANTI-IgE ANTIBODY DERIVATIVES
CN102660569B (zh) 2012-04-21 2013-11-06 大连理工大学 一种重组人IgE受体蛋白的制备方法及应用

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022539684A (ja) * 2019-07-08 2022-09-13 ジーアイ イノベーション， インコーポレイテッド 高シアル酸含量を有し、ＩｇＥ Ｆｃ受容体のアルファサブユニットの細胞外ドメインを含むポリペプチド二量体及び同ポリペプチド二量体を含む医薬組成物
JP7579815B2 (ja) 2019-07-08 2024-11-08 ジーアイ イノベーション， インコーポレイテッド 高シアル酸含量を有し、ＩｇＥ Ｆｃ受容体のアルファサブユニットの細胞外ドメインを含むポリペプチド二量体及び同ポリペプチド二量体を含む医薬組成物
US12409203B2 (en) 2019-07-08 2025-09-09 Gi Innovation, Inc. Polypeptide dimer with high sialic acid content, comprising extracellular domain of alpha subunit of IGE FC receptor, and pharmaceutical composition comprising same
JP2023522574A (ja) * 2020-03-26 2023-05-31 ウニヴェルシテ トゥールーズ トロワジェーム－ポール サバティエ リウマチ性関節炎治療用アフェレシスカラム
JP2023534024A (ja) * 2020-07-17 2023-08-07 ジーアイ イノベーション， インコーポレイテッド Ｉｇｅ ｆｃ受容体アルファサブユニット細胞外ドメイン及び抗ｉｌ－４抗体を含む融合タンパク質並びにその融合タンパク質の使用
JP7784412B2 (ja) 2020-07-17 2025-12-11 ジーアイ イノベーション， インコーポレイテッド Ｉｇｅ ｆｃ受容体アルファサブユニット細胞外ドメイン及び抗ｉｌ－４抗体を含む融合タンパク質並びにその融合タンパク質の使用

Also Published As

Publication number Publication date
CA3010982A1 (en) 2017-07-20
WO2017121842A1 (en) 2017-07-20
US20190127438A1 (en) 2019-05-02
RU2018129024A (ru) 2020-02-13
EP3402813A1 (en) 2018-11-21
AU2017207854A1 (en) 2018-06-07
CN108473551A (zh) 2018-08-31
EP3192806A1 (en) 2017-07-19
RU2018129024A3 (cg-RX-API-DMAC10.html) 2020-05-29

Similar Documents

Publication Publication Date Title
EP3192806A1 (en) Alpha chain of the high-affinity ige receptor (fceria)
Chaudhury et al. Albumin binding to FcRn: Distinct from the FcRn− IgG interaction
JP6152433B2 (ja) 抗ｔｎｆ−抗ｉｌ−１７二重特異性抗体
US12552867B2 (en) Single chain fusionconstructs comprising multimeric antibody fragments fused to collagen trimerization domains
BR122020010972B1 (pt) polipeptídeo isolado e de fusão, sua composição farmacêutica e multímero
WO2013091103A1 (en) Single domain antibodies as inhibitors of pcsk9
JP2022542884A (ja) Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法
EP4386009A1 (en) Bispecific fusion polypeptide and application thereof
JP2016505572A (ja) 改変抗ＩＬ−２３ｐ１９抗体の溶液製剤
CN115666631A (zh) Cd40结合蛋白
TWI878289B (zh) 抗ｃｄ３８抗體和調配物
JP2016027801A (ja) 改良された抗血清アルブミン結合変異体
Vunnam et al. Discovery of a non-competitive TNFR1 antagonist affibody with picomolar monovalent potency that does not affect TNFR2 function
TWI833641B (zh) 適於高濃度組成物及皮下投藥之新穎抗ａｎｇｐｔｌ３抗體
EP4720092A1 (en) Synthetic tnfr1 binding proteins, manufacture, and uses thereof
WO2025255205A1 (en) Synthetic cd123 binding proteins, manufacture, and uses thereof
WO2025193961A1 (en) SYNTHETIC CD16a BINDING PROTEINS, MANUFACTURE, AND USES THEREOF
WO2025193960A1 (en) Synthetic lilrb4-binding proteins, manufacture, and uses thereof
WO2025193981A1 (en) Synthetic multivalent fusion proteins, manufacture, and uses thereof
WO2024155803A2 (en) IgG Fc VARIANTS WITH REDUCED SELF-ASSOCIATION
JP2026500217A (ja) 結合分子
WO2013135748A1 (en) Polypeptides binding to dll4 and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191219

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20200710